Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
Stock Information for IMV Inc.
Loading
Please wait while we load your information from QuoteMedia.